Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers

Frontiers in Oncology

Song Guo Zheng¹  Bo Yang²  Bin Cheng²  Jianbo Sun²  Tingjun Liu²  Hangbo Liu²  Yang Qu² 

[1] Division of Rheumatology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, United States;Guangdong Provincial Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou, China;Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangzhou, China;

关键词: PD-1;    PD-L1;    immune checkpoint inhibitor;    head and neck cancer;    immunotherapy;    adverse effects;   

DOI  :  10.3389/fonc.2018.00563

来源: DOAJ

【 摘 要 】

Head and neck cancer is the 6th most common malignancy worldwide and urgently requires novel therapy methods to change the situation of low 5-years survival rate and poor prognosis. Targeted therapy provides more precision, higher efficiency while lower adverse effects than traditional treatments like surgery, radiotherapy, and chemotherapy. Blockade of PD-1 pathway with antibodies against PD-1 or PD-L1 is such a typical targeted therapy which reconstitutes anti-tumor activity of T cell in treatments of cancers, especially those highly expressing PD-L1, including head and neck cancers. There are many clinical trials all over the world and FDA has approved anti-PD-1/PD-L1 drugs for head and neck cancers. However, with the time going, the dark side of this therapy has emerged, including some serious side effects and drug resistance. Novel materials like nanoparticles and combination therapy have been developed to improve the efficacy. At the same time, standards for evaluation of activity and safety are to be established for this new therapy. Here we provide a systematic review with comprehensive depth on the application of anti-PD1/PD-L1 antibodies in head and neck cancer treatment: mechanism, drugs, clinical studies, influencing factors, adverse effects and managements, and the potential future developments.

【 授权许可】

Unknown